A Phase 2 interventional study of Ivermectin Tablets and Matching placebo tablets in COVID-19, sponsored by MedinCell S.A. Completed at 1 site in Bulgaria. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-12-31.
Sponsored by MedinCell S.A · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies testing ivermectin in COVID-19 — 2 open to participants now, 2 under way, 1 of them phase 3. Ivermectin · COVID-19.
Among the 55 studies testing ivermectin in COVID-19, this one is the 17th largest by enrollment, is one of 5 that started in 2022, is one of 13 in phase 2, and was the 51st registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →2 of the 55 studies testing ivermectin in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:
University of Oxford · Sites in Brazil, Laos, Nepal and 2 more countries
Ages 18–60
UMC Utrecht · Sites in United States, Australia, Belgium and 26 more countries
Ages 28 days+
By country, each count listing its studies:
Ivermectin: first FDA approval 1996 (STROMECTOL). What it is approved for, and how studies give it, is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 26 · Phase 3 26 · Phase 4 5
First in 2016; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 400 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 180 across the 55 interventional studies. Of the 32 that completed or were terminated, 11 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 55 have an industry lead sponsor. The 10 most frequent:
MedinCell S.A is the lead sponsor of 2 studies on the registry; none are open to participants now.
MedinCell S.A has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
1 of the studies testing ivermectin in COVID-19 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05041907University of OxfordFinding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 55 studies testing ivermectin in COVID-19, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A multicenter, randomized, double-blind, placebo-controlled, study to evaluate the efficacy and safety of oral ivermectin tablets versus placebo for COVID-19 prophylaxis
This trial comprises a total observation period of up to 56 days (an on-treatment period of up to 28 days and a safety follow-up of up to 28 days).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ivermectin Tablets
Drug: Matching placebo tablets
Daily ivermectin tablets intake for 28 days ; 200 mcg/kg on D1 then 100 mcg/kg daily from D2 to D28.
Daily placebo tablets intake for 28 days
COVID-19 Prophylaxis
Number of laboratory-confirmed COVID-19 infections in each group between baseline and Day 28
Time frame: From Day 1 to Day 28
COVID-19 Symptoms Development
Number of symptomatic Participants according to the WHO COVID-18 scale
Time frame: From Day 1 to Day 28
COVID-19 Prophylaxis Timeframe
Time to change from baseline in negative RT-PCR to positive RT-PCR
Time frame: From Day 1 to Day 28
COVID-19 Hospitalisations
Proportion of COVID-19 related hospitalisations
Time frame: From Day 1 to Day 56
COVID-19 Mortality
Proportion of COVID-19 related mortality
Time frame: From Day 1 to Day 56
To Assess the Safety and Tolerability of IVM Given for a Period of 28 Days
Descriptive comparison of AE rates and severity/seriousness between IVM and placebo
Time frame: 56 days
| Milestone | Active IMP | Placebo |
|---|---|---|
| Started | 200 | 199 |
| Completed | 200 | 199 |
| Not completed | 0 | 0 |
Number of laboratory-confirmed COVID-19 infections in each group between baseline and Day 28
| Participants | Active IMP | Placebo |
|---|---|---|
| COVID-19 Prophylaxis | 30 | 105 |
Number of symptomatic Participants according to the WHO COVID-18 scale
| Participants | Active IMP | Placebo |
|---|---|---|
| COVID-19 Symptoms Development | 28 | 97 |
Time to change from baseline in negative RT-PCR to positive RT-PCR
| days | Active IMP | Placebo |
|---|---|---|
| COVID-19 Prophylaxis Timeframe | 9 ± 1.39 | 8.10 ± 2.14 |
Proportion of COVID-19 related hospitalisations
| participants | Active IMP | Placebo |
|---|---|---|
| COVID-19 Hospitalisations | 0 | 0 |
Proportion of COVID-19 related mortality
| participants | Active IMP | Placebo |
|---|---|---|
| COVID-19 Mortality | 0 | 0 |
Descriptive comparison of AE rates and severity/seriousness between IVM and placebo
| participants | Active IMP | Placebo |
|---|---|---|
| Adverse events | 49 | 109 |
| Serious adverse events | 0 | 0 |
Collected over 56 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active IMP | 0/200 (0%) | 0/200 (0%) | 49/200 (24.5%) |
| Placebo | 0/199 (0%) | 0/199 (0%) | 109/199 (54.8%) |
| Event | Active IMP | Placebo |
|---|---|---|
| COVID-19Infections and infestations | 30/200 | 109/199 |
| C-reactive protein increasedInvestigations | 0/200 | 5/199 |
| HeadacheNervous system disorders | 4/200 | 1/199 |
| DiarrhoeaGastrointestinal disorders | 4/200 | 0/199 |
| NauseaGastrointestinal disorders | 4/200 | 1/199 |
| Aspartate aminotransferase increasedInvestigations | 3/200 | 0/199 |
| PalpitationsCardiac disorders | 0/200 | 2/199 |
| DysmenorrheaReproductive system and breast disorders | 2/200 | 1/199 |
| FatigueGeneral disorders | 2/200 | 1/199 |
| Alanine aminotransferase increasedInvestigations | 2/200 | 0/199 |
| Age, Continuous(years) | Active IMP | Placebo | Total |
|---|---|---|---|
| Mean | 40.86 ± 11.84 | 39.99 ± 12.03 | 40.42 ± 11.93 |
| Sex: Female, Male(Participants) | Active IMP | Placebo | Total |
|---|---|---|---|
| Female | 81 | 90 | 171 |
| Male | 119 | 109 | 228 |
| Race and Ethnicity Not Collected(Participants) | Active IMP | Placebo | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Active IMP | Placebo | Total |
|---|---|---|---|
| Bulgaria | 200 | 199 | 399 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2022 to primary completion in Sep 2022, 5 months.
Results were first posted in Dec 2024, 2 years 2 months after primary completion.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 5 months is below that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ivermectin
MedinCell S.A